menu
    • menu
    [{"orgOrder":0,"company":"GlycoNex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Denosumab","moa":"Tumor necrosis factor ligand superfamily member 11","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"GlycoNex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"GlycoNex \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GlycoNex \/ Undisclosed"},{"orgOrder":0,"company":"GlycoNex","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2025","type":"Licensing Agreement","leadProduct":"Denosumab","moa":"Tumor necrosis factor ligand superfamily member 11","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"GlycoNex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"GlycoNex \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GlycoNex \/ Undisclosed"},{"orgOrder":0,"company":"GlycoNex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Denosumab","moa":"Tumor necrosis factor ligand superfamily member 11","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"GlycoNex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"GlycoNex \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GlycoNex \/ Undisclosed"},{"orgOrder":0,"company":"GlycoNex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"GNX102","moa":"Tumor-associated glycan antigen (TAGA)","graph1":"Oncology","graph2":"Phase I","graph3":"GlycoNex","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GlycoNex \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GlycoNex \/ Undisclosed"},{"orgOrder":0,"company":"GlycoNex","sponsor":"Sterling Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"GNX102-ADC","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"GlycoNex","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GlycoNex \/ GlycoNex","highestDevelopmentStatusID":"4","companyTruncated":"GlycoNex \/ GlycoNex"},{"orgOrder":0,"company":"GlycoNex","sponsor":"Hokkaido University","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody-drug Conjugate","year":"2025","type":"Collaboration","leadProduct":"GNX1021","moa":"bLeB\/Y","graph1":"Oncology","graph2":"Preclinical","graph3":"GlycoNex","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GlycoNex \/ Hokkaido University","highestDevelopmentStatusID":"4","companyTruncated":"GlycoNex \/ Hokkaido University"},{"orgOrder":0,"company":"GlycoNex","sponsor":"Institute of Science Tokyo | Change Cure","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2025","type":"Collaboration","leadProduct":"CC001","moa":"HMGB1","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"GlycoNex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GlycoNex \/ Institute of Science Tokyo | Change Cure","highestDevelopmentStatusID":"7","companyTruncated":"GlycoNex \/ Institute of Science Tokyo | Change Cure"}]

    Find Clinical Drug Pipeline Developments & Deals by GlycoNex

    Menu

    GlycoNex

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            GlycoNex

                            Taiwan arrow
                            Pharmapack
                            Not Confirmed

                            GlycoNex

                            Taiwan arrow
                            Pharmapack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CC001,Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Institute of Science Tokyo | Change Cure

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            GlycoNex Inks CDMO Deal with Change Cure for HMGB1 Antibody Program

                            Details : The collaboration aims to advance CC001, an unconjugated antibody targeting HMGB1, for frontotemporal lobar degeneration.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            December 08, 2025

                            Lead Product(s) : CC001,Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Institute of Science Tokyo | Change Cure

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            GlycoNex

                            Taiwan arrow
                            Pharmapack
                            Not Confirmed

                            GlycoNex

                            Taiwan arrow
                            Pharmapack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GNX1021

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Hokkaido University

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            GlycoNex, Hokkaido Hospital Study Glycan-Directed ADCs in Gastric Cancer

                            Details : The deal aims to advance GNX1021, an Antibody-drug Conjugate targeting bLeB/Y.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            November 24, 2025

                            Lead Product(s) : GNX1021

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Hokkaido University

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            GlycoNex

                            Taiwan arrow
                            Pharmapack
                            Not Confirmed

                            GlycoNex

                            Taiwan arrow
                            Pharmapack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Denosumab

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            GlycoNex Announces Licensing Agreement for SPD8 Biosimilar

                            Details : Under the terms of agreement, the licensee will obtain rights to develop, secure regulatory approval for, and commercialize SPD8 (Denosumab) biosimilar to Prolia for the treatment of osteoporosis.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            January 06, 2025

                            Lead Product(s) : Denosumab

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            GlycoNex

                            Taiwan arrow
                            Pharmapack
                            Not Confirmed

                            GlycoNex

                            Taiwan arrow
                            Pharmapack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Denosumab

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            GlycoNex Announces First Patient Dosed in Phase 3 Clinical Trial for Denosumab Biosimilar

                            Details : SPD8 (denosumab) is a biosimilar of Prolia and Xgeva, designed for use in postmenopausal women with osteoporosis. This medication is administered subcutaneously and functions as a RANKL inhibitor.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            December 17, 2024

                            Lead Product(s) : Denosumab

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            GlycoNex

                            Taiwan arrow
                            Pharmapack
                            Not Confirmed

                            GlycoNex

                            Taiwan arrow
                            Pharmapack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GNX102-ADC

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Sterling Pharma Solutions

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            GlycoNex Partners with Sterling for GNX102-ADC Clinical Trial Production

                            Details : The agreement aims for clinical trial production of GNX102-ADC in preparation for a planned Phase 1 clinical program investigating the drug technology.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            November 12, 2024

                            Lead Product(s) : GNX102-ADC

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Sterling Pharma Solutions

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            GlycoNex

                            Taiwan arrow
                            Pharmapack
                            Not Confirmed

                            GlycoNex

                            Taiwan arrow
                            Pharmapack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Denosumab

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            GlycoNex Successfully Completes Phase 1 Study of Denosumab Biosimilar, SPD8

                            Details : SPD8 (denosumab) is a biosimilar of Prolia and Xgeva, designed for use in postmenopausal women with osteoporosis. This medication is administered subcutaneously and functions as a RANKL inhibitor.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            August 19, 2024

                            Lead Product(s) : Denosumab

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            GlycoNex

                            Taiwan arrow
                            Pharmapack
                            Not Confirmed

                            GlycoNex

                            Taiwan arrow
                            Pharmapack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GNX102

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of GNX102 in Patients With Advanced Solid Tumors

                            Details : GNX102 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            January 31, 2020

                            Lead Product(s) : GNX102

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.